Patients with high-risk GEP results may benefit from adjuvant immune checkpoint inhibitors (nivolumab and pembrolizumab) or targeted therapies (BRAF/MEK inhibitors in BRAF-mutant melanoma). This evidence concerns the gene BRAF and melanoma.